Chiron Capital Management LLC Invests $208,000 in Align Technology, Inc. $ALGN

Chiron Capital Management LLC acquired a new position in Align Technology, Inc. (NASDAQ:ALGN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,100 shares of the medical equipment provider’s stock, valued at approximately $208,000.

Several other large investors have also bought and sold shares of the stock. Federated Hermes Inc. grew its position in shares of Align Technology by 510.3% in the 1st quarter. Federated Hermes Inc. now owns 707,514 shares of the medical equipment provider’s stock valued at $112,396,000 after buying an additional 591,588 shares during the last quarter. Mackenzie Financial Corp lifted its stake in shares of Align Technology by 4,217.3% in the first quarter. Mackenzie Financial Corp now owns 426,205 shares of the medical equipment provider’s stock worth $67,707,000 after acquiring an additional 416,333 shares during the period. Nordea Investment Management AB lifted its stake in shares of Align Technology by 94.5% in the second quarter. Nordea Investment Management AB now owns 638,341 shares of the medical equipment provider’s stock worth $121,055,000 after acquiring an additional 310,091 shares during the period. AQR Capital Management LLC boosted its holdings in Align Technology by 104.2% in the first quarter. AQR Capital Management LLC now owns 404,310 shares of the medical equipment provider’s stock valued at $63,133,000 after acquiring an additional 206,308 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Align Technology by 32.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 832,313 shares of the medical equipment provider’s stock valued at $132,221,000 after purchasing an additional 202,616 shares during the period. 88.43% of the stock is owned by institutional investors.

Align Technology Trading Down 1.6%

Shares of NASDAQ ALGN opened at $137.13 on Monday. The firm has a market capitalization of $9.84 billion, a P/E ratio of 26.58, a P/E/G ratio of 1.49 and a beta of 1.84. The firm’s 50-day moving average price is $132.91 and its 200-day moving average price is $159.04. Align Technology, Inc. has a 1-year low of $122.00 and a 1-year high of $246.19.

Align Technology (NASDAQ:ALGN) last issued its earnings results on Wednesday, October 29th. The medical equipment provider reported $2.61 EPS for the quarter, beating analysts’ consensus estimates of $2.38 by $0.23. Align Technology had a return on equity of 14.06% and a net margin of 9.50%.The business had revenue of $995.69 million during the quarter, compared to analyst estimates of $980.75 million. During the same period in the previous year, the company posted $2.35 EPS. The firm’s revenue was up 1.8% compared to the same quarter last year. Align Technology has set its Q4 2025 guidance at EPS. Equities research analysts forecast that Align Technology, Inc. will post 7.98 EPS for the current year.

Align Technology declared that its Board of Directors has initiated a share repurchase program on Tuesday, August 5th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the medical equipment provider to purchase up to 2% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ALGN. Zacks Research upgraded shares of Align Technology from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 30th. Morgan Stanley boosted their target price on shares of Align Technology from $142.00 to $154.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Wall Street Zen raised shares of Align Technology from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Leerink Partners lifted their price objective on Align Technology from $172.00 to $189.00 in a research report on Thursday, October 30th. Finally, Piper Sandler restated an “overweight” rating and set a $200.00 target price (up previously from $190.00) on shares of Align Technology in a research report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $175.45.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.